At the conclusion of this activity, learners should be able to:

• Describe clinical trial data showing variation in how RAS mutant cancers respond to treatment
• Describe ongoing studies subclassifying RAS mutants into those that are biomarkers for EGFR inhibitor sensitivity and for EGFR inhibitor resistance
• Identify computational simulations as an emerging computational tool for studying pathogenic mutations and their response to treatment